JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M112224200 on February 27, 2002

J. Biol. Chem., Vol. 277, Issue 18, 15607-15612, May 3, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/18/15607    most recent
M112224200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, N. A.
Right arrow Articles by Kim, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, N. A.
Right arrow Articles by Kim, K. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cytotoxic Necrotizing Factor-1 Contributes to Escherichia coli K1 Invasion of the Central Nervous System*

Naveed Ahmed KhanDagger , Ying Wang§, Kee Jun KimDagger , Jin Woong ChungDagger , Carol Ann Wass§, and Kwang Sik KimDagger §

From the § Division of Infectious Diseases, Childrens Hospital Los Angeles, University of Southern California School of Medicine, Los Angeles, California 90027 and the Dagger  Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Received for publication, December 20, 2001, and in revised form, February 1, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Escherichia coli K1 invasion of brain microvascular endothelial cells (BMECs) is a prerequisite for penetration into the central nervous system and requires actin cytoskeletal rearrangements. Here, we demonstrate that E. coli K1 invasion of BMECs requires RhoA activation. In addition, we show that cytotoxic necrotizing factor-1 (CNF1) contributes to E. coli K1 invasion of brain endothelial cells in vitro and traversal of the blood-brain barrier in the experimental hematogenous meningitis animal model. These in vitro and in vivo effects of CNF1 were dependent upon RhoA activation as shown by (a) decreased invasion and RhoA activation with the Delta cnf1 mutant of E. coli K1 and (b) restoration of invasion frequency of the Delta cnf1 mutant to the level of the parent E. coli K1 strain in BMECs with constitutively active RhoA. In addition, CNF1-enhanced E. coli invasion of brain endothelial cells and stress fiber formation were independent of focal adhesion kinase and phosphatidylinositol 3-kinase activation. This is the first demonstration that CNF1 contributes to E. coli K1 invasion of BMECs.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inadequate knowledge of the pathogenesis associated with bacterial entry into the central nervous system contributes to considerable mortality and morbidity associated with bacterial meningitis. For example, most cases of bacterial meningitis occur as a result of hematogenous spread, but it is unclear how circulating bacteria cross the blood-brain barrier (1). Escherichia coli is the most common Gram-negative microorganism causing meningitis in the neonatal period. We have previously shown that E. coli K1 crossing of the blood-brain barrier in vivo requires a threshold level of bacteremia and invasion of brain microvascular endothelial cells (BMECs)1 and identified several E. coli determinants (OmpA, Ibe proteins, AslA, and TraJ) contributing to BMEC invasion in vitro and in vivo (2-7). We have also demonstrated that host cell actin cytoskeletal rearrangements are required for E. coli K1 invasion of BMECs, as shown by invasive E. coli K1-associated F-actin condensation and blockade of E. coli K1 invasion of BMECs by the microfilament-disrupting agents cytochalasin D and latrunculin A (8); but the specific host cell signaling pathways involved in E. coli K1 invasion and actin cytoskeletal rearrangements remain incompletely understood.

Our recent studies have shown that tyrosine phosphorylation of several host cell signaling molecules is involved in E. coli K1 invasion of BMECs, as treatment of BMECs with genistein, a protein-tyrosine kinase inhibitor, blocks E. coli K1 invasion of BMECs (9). In addition, focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) are crucial signaling pathways contributing to E. coli K1 invasion of BMECs (9, 10), but the basis of E. coli K1 activation of FAK and PI3K has yet to be defined. It is also unclear which microbial factors contribute to actin cytoskeletal rearrangements in BMECs.

Cytotoxic necrotizing factor-1 (CNF1) is a dermonecrotic protein toxin produced by human and animal isolates of E. coli. CNF1 consists of 1014 amino acids with a molecular mass of 113.7 kDa. CNF1 is frequently associated with E. coli strains that cause extraintestinal infections in humans (11, 12). However, the exact role of CNF1 in the pathogenesis of extraintestinal E. coli infections is not fully understood. Previous studies have indicated that CNF1 induces phagocytosis in epithelial cells (13-15). CNF1 has been shown to activate Rho GTPases by deamidation of glutamine 63, converting it into glutamic acid, thereby inhibiting GTP-hydrolyzing activity and constitutive activation of Rho, resulting in polymerization of F-actin and increased formation of stress fibers (16-18). In this study, we examined the role of CNF1 in E. coli K1 invasion of BMECs in vitro and traversal of the blood-brain barrier in the experimental hematogenous meningitis animal model and the mechanisms associated with CNF1 in E. coli K1 invasion of BMECs.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial Strains and Culture Conditions-- E. coli K1 strain E44 is a spontaneous rifampin-resistant mutant of strain RS218 (O18:K1:H7), a cerebrospinal fluid isolate from a neonate with meningitis (4). E. coli K12 strain JM101 (New England Biolabs Inc., Beverly, MA) was used as the host for plasmids, and SM10 lambda pir (19) was used as the host for suicide plasmids. E. coli strains were routinely grown at 37 °C in Luria broth. Where appropriate, the medium was supplemented with ampicillin (100 µg/ml), kanamycin (40 µg/ml), chloramphenicol (25 µg/ml), or rifampin (50 µg/ml).

Construction of the cnf1 Deletion Mutant-- Oligonucleotide primers were designed based on the published sequence of the cnf1 gene (20). A 1-kb DNA fragment was obtained using primers 5'-GGCAGCCATTTGATTTTG-3' and 5'-TTCCGCTTGTAATGATTAC-3' and cloned into pBluescript KS (Stratagene, La Jolla, CA). A 0.9-kb DNA fragment upstream of cnf1 was produced using primers 5'-ACGGATCCCGCGACGGAAGCT-3', incorporating a BamHI site (underlined), and 5'-AAGAATTCTTAATGTAATCGCT-3', incorporating an EcoRI site (underlined), and cloned into the above-mentioned plasmid; and then a kanamycin resistance cassette from pUC4K (Amersham Biosciences) was inserted at the EcoRI site. The recombinant DNA was moved to suicide plasmid pET185.2 and then transferred to strain E44 by conjugation. The cnf1 deletion mutant was selected on kanamycin and verified by PCR.

Purification of CNF1-- The cnf1 gene was amplified from E. coli K1 strain E44 using oligonucleotide primers 5'-ACGGATCCCGCGACGGAAGCT-3', incorporating a BamHI site (underlined), and 5'-ACGAATTCTCATTTGTTTGCCTT-3', incorporating an EcoRI site (underlined), and cloned into pBluescript KS at the same sites to produce pB-cnf1. CNF1 was expressed in E. coli JM101 and purified using published protocols (14).

Endothelial Cell Cultures and Transfections-- Human BMECs were isolated and cultured as previously described (21). BMEC cultures were grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, 10% NuSerum, 2 mM glutamine, 1 mM pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin, essential amino acids, and vitamins. PI3K mutants Delta p110 (a kinase-negative catalytic subunit of PI3K) and Delta p85 (defective in interaction with p110) were prepared as previously described (10). A FAK mutant lacking the autophosphorylation site (Phe397FAK) was prepared as described previously (9). Dominant-negative RhoA (N19RhoA, constructed by replacing threonine 19 with asparagine) and constitutively active RhoA (V14RhoA, constructed by replacing glycine 14 with valine using oligonucleotide-directed mutagenesis) constructs were used as previously described (22, 23). All constructs were cloned into the pCMV-based vector pcDNA3 (Invitrogen) and transfected into human BMECs using LipofectAMINE (Invitrogen) as previously described (10). Briefly, a DNA-LipofectAMINE complex in RPMI 1640 medium was added to 50% confluent human BMEC monolayers. After 6 h of incubation, cells were washed and grown in complete medium for 72 h, followed by selection with G418 (400 µg/ml). Antibiotic-resistant colonies were pooled and confirmed by Western blotting.

In Vitro Human BMEC Invasion Assays-- Invasion assays were performed as previously described (4, 9). Confluent cultures of human BMECs (grown in 24-well plates) were incubated with 107 E. coli cells (multiplicity of infection of 100) in experimental medium (Medium 199/Ham's F-12 medium (1:1) containing 5% heat-inactivated fetal bovine serum, 2 mM glutamine, and 1 mM pyruvate). Plates were incubated at 37 °C in a 5% CO2 incubator for 90 min. Monolayers were washed with RPMI 1640 medium and incubated with experimental medium containing gentamicin (100 µg/ml) for 1 h to kill extracellular bacteria. The monolayers were washed again and lysed in 0.5% Triton X-100. The released intracellular bacteria were enumerated by plating on sheep blood agar plates. To examine the role of RhoA in E. coli invasion of human BMECs, cells were treated with the Rho kinase inhibitor Y-27632 (Calbiochem) (24), and invasion assays were performed. To determine the effects of CNF1 on E. coli K1 invasion, monolayers were incubated with CNF1 in experimental medium for 2 h before addition of the bacteria.

Rat Model of E. coli K1 Meningitis-- The cnf1 deletion mutant was examined for its ability to enter the central nervous system using our neonatal rat model of hematogenous E. coli meningitis as previously described (25). Briefly, at 5 days of age, all members of each litter were randomly divided into two groups to receive subcutaneously 105 colony-forming units of E. coli K1 strain E44 or its cnf1 deletion mutant. At 18 h after bacterial inoculation, blood and cerebrospinal fluid specimens were obtained for quantitative cultures. The development of meningitis was defined as positive cerebrospinal fluid cultures. All experiments were performed in compliance with National Institutes of Health and institutional guidelines.

Immunofluorescence Assays for Determination of Stress Fiber Formation-- Human BMECs were stimulated with CNF1 for 2 h and fixed with 4% paraformaldehyde in phosphate-buffered saline for 15 min at room temperature. Following fixation, cells were permeabilized with 0.3% saponin in phosphate-buffered saline for 30 min at room temperature. Finally, cells were incubated with rabbit polyclonal antibody against actin (Sigma) for 60 min at room temperature, followed by incubation with TRITC-labeled anti-rabbit antibody for 60 min at room temperature, and visualized under an immunofluorescence microscope (8).

Western Blotting for Detection of GTP-RhoA-- Human BMECs were lysed in radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 7.4), 0.1% SDS, 0.5% sodium deoxycholate, 10 mM sodium pyrophosphate, 25 mM beta -glycerophosphate, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin). Samples were centrifuged at 10,000 × g for 6 min at 4 °C, and the supernatant was collected for protein quantification.

An equal amount of protein (500 µg to 1 mg) was incubated with glutathione S-transferase-rhotekin (Upstate Biotechnologies, Inc., Lake Placid, NY) for 45 min at 4 °C to collect active forms of RhoA, i.e. GTP-RhoA. The protein complex was washed with radioimmune precipitation assay buffer, resolved by 10% SDS-PAGE, and transferred to nitrocellulose membrane. The blots were blocked with 25 mM Tris (pH 7.4), 150 mM NaCl, and 0.1% Tween 20 containing 4% skim milk for 60 min at 22 °C. After blocking, the membranes were incubated overnight at 4 °C with mouse monoclonal antibody against RhoA (Santa Cruz Biotechnology, Santa Cruz, CA) and subsequently incubated for 60 min at 22 °C with horseradish peroxidase-linked secondary antibody against mouse. Antibody-bound RhoA was visualized using an enhanced chemiluminescence kit (Amersham Biosciences) (26). A single band of RhoA in the 21-kDa range was detected.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The cnf1 Deletion Mutant of E. coli K1 Is Less Efficient in Invasion of Human BMECs in Vitro and Penetration of the Blood-Brain Barrier in the Hematogenous Meningitis Model in Vivo-- To determine whether CNF1 plays a role in E. coli K1 invasion of BMECs, an isogenic E44 mutant (Delta cnf1) was generated (Fig. 1). The deletion of cnf1 in the mutant strain was verified by PCR (data not shown) as well as by Western blotting (Fig. 2). The growth characteristics of strain E44 and the Delta cnf1 mutant were identical on Luria broth and blood agar. In addition, the total protein profiles as assessed by SDS-PAGE were identical for strain E44 and the Delta cnf1 mutant (data not shown). Both strain E44 and the Delta cnf1 mutant were used for invasion assays. We observed that the cnf1 deletion mutant was significantly less invasive in BMECs compared with the parent strain (Fig. 3). To examine whether the cnf1 deletion mutant is indeed less invasive in vivo, the cnf1 mutant and the parent strain were administered to 5-day-old rats. As shown in Table I, subcutaneous injection of 105 colony-forming units of strain E44 or its cnf1 mutant resulted in bacteremia in 100% of the animals, and the magnitude of the bacteremia was similar between the two groups. A total of 10 of 26 animals (38%) infected with strain E44 were found to have meningitis. In contrast, only 3 of 28 animals (11%) developed meningitis, and this rate of meningitis was significantly less (p = 0.026) than the rate observed with the cnf1 mutant. These findings indicate that CNF1 is a critical determinant for E. coli K1 to invade human BMECs in vitro and to cross the blood-brain barrier in vivo. It is also important to recognize that the frequency of in vitro BMEC invasion (~0.1%) corresponds to the enhanced bacterial penetration of the blood-brain barrier in vivo (Fig. 3 and Table I) (2-4, 7).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Detailed map of the cnf1 deletion mutant. Shown is the organization of the cnf1 deletion DNA compared with its parent strain (E44) and plasmid pBluescript KS cloned with cnf1. Restriction sites are as follows: E1, EcoRI; A, AccI; Bg, BglII; Ev, EcoRV; P, PstI; X, XmnI.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   Western blot showing CNF1 from strain E44, its cnf1 deletion mutant, and strain JM101 containing pBluescript KS cloned with cnf1. Bacterial strain E44, its cnf1 deletion mutant, and strain JM101 containing plasmid cloned with cnf1 were grown overnight. Total bacterial lysates were electrophoresed on polyacrylamide gel, transferred to nitrocellulose membrane, and Western-blotted using anti-CNF1 polyclonal antibody. Note that the cnf1 deletion mutant of strain E44 did not exhibit CNF1 expression.


View larger version (5K):
[in this window]
[in a new window]
 
Fig. 3.   The cnf1 deletion mutant of E. coli K1 strain E44 (O18:K1:H7) exhibits decreased invasion of human BMECs. To determine whether CNF1 plays a role in the E44 invasion of BMECs, invasion assays were performed using the cnf1 deletion mutant of strain E44 in human BMECs (25). A significant decrease in the invasion of BMECs was observed with the mutant compared with its parent strain. A noninvasive laboratory E. coli strain (HB101) was used as a negative control. Error bars indicate S.D. Data represent the average of three independent experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of number of animals with positive cerebrospinal fluid cultures for E. coli between two groups of animals receiving E. coli K1 strain E44 or its cnf1 deletion mutant

Requirement of RhoA in E. coli K1 Invasion of Human BMECs-- To determine the role of RhoA in E. coli K1 invasion of human BMECs, monolayers were treated with Y-27632 (a Rho kinase inhibitor), and invasion assays were performed. Y-27632 exhibited a dose-dependent inhibition of E. coli K1 invasion of human BMECs (Fig. 4), suggesting that RhoA plays a role in E. coli K1 invasion of human BMECs. To further confirm these findings, invasion assays were performed using BMECs expressing dominant-negative RhoA (Delta RhoA) or BMECs with constitutively active RhoA (RhoA). E. coli K1 invasion was decreased by >50% in human BMECs expressing dominant-negative RhoA (Fig. 5 and Table II), whereas BMECs with constitutively active RhoA exhibited a marked increase in E. coli K1 invasion of human BMECs (Fig. 5). Taken together, these findings indicate that RhoA activation is required for efficient E. coli K1 invasion of human BMECs.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 4.   The Rho kinase inhibitor Y-27632 blocks E. coli K1 invasion of human BMECs. E. coli invasion assays were performed with human BMECs treated with the Rho kinase inhibitor Y-27632 at different concentrations for 30 min. Control invasion assays were performed without prior Y-27632 treatment. Note that Y-27632 (Y) at both 10 and 50 µM significantly decreased E. coli K1 invasion of human BMECs (p < 0.05, calculated using an unpaired t test with Slide Write Plus Version 3 for Windows). Experiments were performed in triplicates. Error bars represent S.D.


View larger version (7K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of dominant-negative RhoA decreases BMEC invasion by E. coli K1 strain E44, whereas expression of constitutively active RhoA increases BMEC invasion by strain E44 as well as by its cnf1 deletion mutant. Human BMECs were transfected with pcDNA3 cloned with dominant-negative RhoA (N19RhoA) or constitutively active RhoA (V14RhoA) as described under "Experimental Procedures." As controls, cells were transfected with pcDNA3 alone. Invasion assays were performed using E. coli K1 strain E44 or its cnf1 deletion mutant. Note that E44 invasion was decreased in dominant-negative RhoA-expressing BMECs, whereas the cnf1 deletion mutant was able to invade human BMECs exhibiting constitutively active RhoA to the level of parent strain E44.

                              
View this table:
[in this window]
[in a new window]
 
Table II
CNF1 increases E. coli K1 invasion in pcDNA-transfected BMECs as well as in dominant-negative FAK- and PI3K-expressing BMECs, but not in dominant-negative RhoA-expressing BMECs or in the presence of the Rho kinase inhibitor Y-27632

The cnf1 Deletion Mutant Is Less Efficient in RhoA Activation-- Rho GTPases, shown to affect actin cytoskeletal rearrangements, are the target of CNF1 (13, 16, 17). To assess whether the cnf1 deletion mutant lacks the ability of RhoA activation, human BMECs were incubated with E. coli K1 strain E44 and its cnf1 deletion mutant, and total lysates were compared for the activated GTP form of RhoA. The cnf1 deletion mutant was significantly less efficient in activation of RhoA GTPase compared with parent strain E44 (p < 0.05) (Fig. 6, a and b). Of interest, the cnf1 deletion mutant of E44 exhibited increased RhoA activation compared with the negative control (laboratory E. coli strain HB101) (Fig. 6, a and b). We have previously shown that several E. coli determinants such as OmpA, Ibe proteins, AslA, and TraJ contribute to BMEC invasion (2-7), and it may be possible that one or more of these microbial determinants also contribute to RhoA activation. Overall, these findings suggest that CNF1 contributes to E. coli K1 invasion of BMECs most likely via RhoA activation. This concept was further supported by the demonstration that the invasive ability of the cnf1 deletion mutant was restored to the level of the parent E. coli K1 strain in BMECs with constitutively active RhoA (Fig. 5).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 6.   The cnf1 deletion mutant of E. coli K1 strain E44 (O18:K1:H7) exhibits decreased RhoA activation. a, RhoA activation (GTP-RhoA) was significantly reduced with the cnf1 deletion mutant compared with parent strain E44 (p < 0.05, calculated from the density of the bands using an unpaired t test with Slide Write Plus Version 3 for Windows). Control indicates BMECs treated with HB101. Human BMECs were treated with E44 and its cnf1 deletion mutant, and GTP-RhoA was collected as described under "Experimental Procedures." Western blotting was performed using anti-RhoA antibody (26). Before performing glutathione S-transferase-rhotekin incubation, an aliquot of each sample was analyzed by Western blotting using anti-RhoA antibody, showing equal amounts of proteins in all samples. b, quantitation of the GTP-RhoA bands in a was performed. The density of the GTP-RhoA bands was quantitated using an imaging densitometer. Data represent the average of three independent experiments. Error bars indicate S.D.

CNF1 Treatment Dramatically Increases E. coli K1 Invasion of Human BMECs-- Next, to determine the effects of CNF1 on E. coli K1 invasion, we incubated human BMECs with purified CNF1 for 2 h prior to invasion assays. A >40-fold increase in E. coli K1 invasion of BMECs was observed in CNF1-treated cells (Table II). We previously reported that tyrosine phosphorylations of FAK and PI3K are essential for E. coli K1 invasion of human BMECs, as shown by significantly decreased invasion of E. coli K1 in dominant-negative FAK- and PI3K-expressing BMECs (Table II) (9, 10). However, CNF1-mediated E. coli K1 invasion of human BMECs was independent of FAK and PI3K. This was shown by the demonstration that CNF1 enhanced E. coli K1 invasion of pcDNA-transfected BMECs as well as of both dominant-negative FAK- and PI3K-expressing BMECs (Table II).

However, prior treatment of dominant-negative RhoA-expressing BMECs with CNF1 resulted in a minimal increase in E. coli K1 invasion, documenting that RhoA is the major target in CNF1-mediated invasion of E. coli K1 in human BMECs. In addition, human BMECs were treated with Y-27632 and then with CNF1, followed by the invasion assays. We observed that CNF1 did not increase invasion substantially in cells that were pretreated with Y-27632 (Table II), thus further confirming that CNF1-mediated increased E. coli K1 invasion of human BMECs requires RhoA activation.

CNF1 Induces Stress Fiber Formation in Human BMECs-- We have demonstrated that host cell actin cytoskeletal rearrangements are required for E. coli K1 invasion of BMECs (8). CNF1 has been shown to activate Rho GTPases, resulting in polymerization of F-actin and increased formation of stress fibers in human umbilical vein endothelial cells (18). To determine whether CNF1 induces stress fiber formation in human BMECs, cells were incubated with CNF1 for 2 h, and immunofluorescence assays were performed. We observed increased stress fiber formation in CNF1-treated pcDNA-transfected BMECs (Fig. 7). Consistent with the above invasion data, CNF1-induced stress fiber formation was also observed in both dominant-negative FAK- and PI3K-expressing BMECs (Fig. 7). In contrast, CNF1 did not induce stress fiber formation in dominant-negative RhoA-expressing BMECs (Fig. 7) and in Y-27632-pretreated BMECs (data not shown).


View larger version (106K):
[in this window]
[in a new window]
 
Fig. 7.   CNF1-mediated stress fiber formation is dependent on RhoA. CNF1 was incubated with BMECs transfected with pcDNA3 alone or with pcDNA3 encoding dominant-negative RhoA, FAK, and PI3K. BMECs were fixed and stained with anti-actin antibody and visualized under immunofluorescence. Note that CNF1 increased stress fiber formation in both dominant-negative FAK- and PI3K-expressing BMECs, but not in dominant-negative RhoA-expressing cells. Data represent the average of three independent experiments.

CNF1-mediated Invasion and Cytoskeletal Rearrangements Are Independent of FAK and PI3K, but Dependent on RhoA-- To verify the activation of RhoA following CNF1 treatment, human BMECs were stimulated with CNF1 for 30 min, and GTP-RhoA was collected as described under "Experimental Procedures." We observed increased levels of GTP-RhoA in response to CNF1 in pcDNA-transfected BMECs as well as in both dominant-negative FAK- and PI3K-expressing BMECs (Fig. 8, a and b). CNF1 treatment of dominant-negative RhoA-expressing BMECs did not result in RhoA activation (Fig. 8, a and b). Taken together, these findings indicate that CNF1-mediated E. coli K1 invasion of BMECs and cytoskeletal rearrangements are independent of FAK and PI3K, but dependent on RhoA.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 8.   CNF1 activation of RhoA is independent of PI3K and FAK. a, BMECs expressing pcDNA3 or dominant-negative RhoA, PI3K, or FAK were treated with CNF1 for 30 min, and GTP-RhoA was collected as described under "Experimental Procedures." b, quantitation of the GTP-RhoA bands in a was carried out. Data represent the average of three independent experiments. Error bars indicate S.D.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To our knowledge, this is the first report describing the role of CNF1 in the pathogenesis of meningitis due to E. coli K1. The cnf1 deletion mutant was significantly less invasive in human BMECs in vitro as well as significantly less efficient in penetration of the blood-brain barrier in the experimental hematogenous E. coli meningitis animal model in vivo compared with the parent E. coli K1 strain. We have previously shown that a high degree of bacteremia is a primary determinant for meningeal invasion by E. coli K1 (27); however, the magnitude of bacteremia was similar between the two groups of animals infected with the cnf1 deletion mutant or the parent strain (Table I). These findings indicate that CNF1 is indeed a critical determinant for E. coli K1 penetration of the central nervous system in vivo. This finding is in contrast to previous reports describing the inconsistent contribution of CNF1 to uropathogenesis in vivo (28-30).

We have previously shown that FAK and PI3K are essential for E. coli K1 invasion of human BMECs (Table II) (9, 10). In addition, we have shown that PI3K interacts with FAK in human BMECs and that its interaction is increased in human BMECs stimulated with E. coli K1 (9, 10), suggesting that FAK recruits PI3K to the sites of bacterial entry. PI3K activation is abolished in dominant-negative FAK mutants (10), indicating that FAK is upstream of PI3K in E. coli K1 invasion of human BMECs. CNF1 has been shown to enhance tyrosine phosphorylation of FAK and formation of stress fibers in Swiss 3T3 fibroblasts (31). In contrast, as shown in this study, increased stress fiber formation and E. coli K1 invasion in response to CNF1 in human BMECs were independent of FAK and PI3K. These findings suggest that the requirement of FAK and PI3K for E. coli K1 invasion of human BMECs was overcome by CNF1 treatment of human BMECs. We have previously shown that several determinants of E. coli K1 such as OmpA and Ibe proteins contribute to BMEC invasion (2-7), and it is tempting to speculate that the contribution of OmpA and Ibe proteins to E. coli K1 invasion of BMECs may involve FAK and PI3K. Additional studies are needed to determine microbial factors contributing to E. coli K1 invasion of BMECs and also requiring FAK and PI3K activation.

One of the novel findings in this study is that E. coli K1 invasion of human BMECs was dependent on Rho GTPase. This was shown using dominant-negative RhoA-expressing BMECs as well as the Rho kinase inhibitor Y-27632, both of which showed significant decreases in E. coli K1 invasion of human BMECs. Of interest, the cnf1 deletion mutant was significantly less efficient in invasion of human BMECs as well as in RhoA activation compared with the parent E. coli K1 strain, suggesting that CNF1 contributes to E. coli K1 invasion of BMECs via RhoA activation. This concept was further supported by the demonstration that the decreased invasion observed with the cnf1 deletion mutant was restored to the level of the parent E. coli K1 strain using BMECs with constitutively active RhoA. Also, similar to the enhancing effects of CNF1 on E. coli K1 invasion of BMECs, invasion assays using BMECs with constitutively active RhoA resulted in significantly increased invasion, suggesting that RhoA activation can substitute for CNF1 in enhancing E. coli K1 invasion of BMECs. Taken together, these findings suggest that CNF1 mediates E. coli K1 invasion of BMECs via RhoA activation. Of interest, the enhancing effects of constitutively active RhoA on E. coli K1 invasion were not as high as those achieved using CNF1 (~8-fold versus 40-fold increases, respectively). One explanation may be the use of different methods of activating RhoA, i.e. transfection versus CNF1 treatment. An alternative explanation may be related to the concept that CNF1 may activate RhoA and other Rho GTPases, resulting in greater E. coli K1 invasion of BMECs.

In their active GTP-bound form, Rho GTPases interact with many effectors, including serine/threonine kinases, lipid kinases, and several adaptor proteins (32-34), affecting the host cell actin cytoskeleton and leading to increased formation of stress fibers (14, 15, 18, 31). Several lines of evidence suggest that PI3K plays an important role in host cell cytoskeletal remodeling and trafficking (35). For example, PI3K controls Rho-mediated changes in the actin cytoskeleton in fibroblasts (36, 37). We showed that CNF1 treatment increased stress fiber formation in dominant-negative PI3K-expressing BMECs, whereas this effect was minimal in dominant-negative RhoA-expressing BMECs and in Y-27632-pretreated BMECs. In addition, RhoA activation (as shown by GTP-RhoA) was shown to occur in response to CNF1 in dominant-negative PI3K-expressing BMECs. Overall, these data indicate that E. coli K1-induced stress fiber formation of BMECs is dependent upon RhoA, FAK, and PI3K, but that CNF1 treatment is able to overcome the requirement of FAK and PI3K, suggesting different mechanisms for E. coli K1 and CNF1 for their abilities to induce stress fiber formation and also to induce bacterial entry into human BMECs.

We have previously documented that other meningitis-causing bacteria such as group B Streptococcus (38) and Citrobacter (39) are able to invade human BMECs by inducing host cell actin cytoskeletal rearrangements, but the basis of actin cytoskeletal rearrangements by these meningitis-causing bacteria is unclear. In this study, we demonstrated that CNF1 contributes to E. coli K1 invasion of BMECs by modulating actin cytoskeletal rearrangements through activation of RhoA. More importantly, we identified CNF1 as a critical determinant for E. coli K1 penetration of the central nervous system in vivo. Our findings with CNF1-producing E. coli K1 illustrate that CNF1 in a whole bacterium is able to contribute to BMEC invasion in vitro and penetration into the central nervous system in vivo. In contrast, previous reports describing CNF1-mediated enhancement of bacterial invasion of host cells have shown with addition of only exogenous CNF1 (14). Of interest, CNF1 is considered to be a cytosolic protein and not to be secreted from the whole bacterium. It remains unclear how CNF1 in the whole bacterium is able to provide the BMEC invasion phenotype and RhoA activation, and studies are in progress to address this issue.

    ACKNOWLEDGEMENTS

We thank A. Hall and M. Schwartz for providing dominant-negative RhoA (N19RhoA) and constitutively active RhoA (V14RhoA) constructs.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants NS 26310, AI 47225, and HL 61951.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Park 256, Baltimore, MD 21287. Tel.: 410-614-3917; Fax: 410-614-1491; E-mail: kwangkim@jhmi.edu.

Published, JBC Papers in Press, February 27, 2002, DOI 10.1074/jbc.M112224200

    ABBREVIATIONS

The abbreviations used are: BMECs, brain microvascular endothelial cells; FAK, focal adhesion kinase; PI3K, phosphatidylinositol 3-kinase; CNF1, cytotoxic necrotizing factor-1; TRITC, tetramethylrhodamine isothiocyanate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kim, K. S. (2000) Subcell. Biochem. 33, 47-59[Medline] [Order article via Infotrieve]
2. Badger, J. L., Wass, C. A., Weissman, S. J., and Kim, K. S. (2000) Infect. Immun. 68, 5056-5061[Abstract/Free Full Text]
3. Hoffman, J. A., Badger, J. L., Zhang, Y., Huang, S. H., and Kim, K. S. (2000) Infect. Immun. 68, 5062-5067[Abstract/Free Full Text]
4. Huang, S. H., Chen, Y. H., Fu, Q., Stins, M., Wang, Y., Wass, C., and Kim, K. S. (1999) Infect. Immun. 67, 2103-2109[Abstract/Free Full Text]
5. Prasadarao, N. V., Wass, C. A., Weiser, J. N., Stins, M. F., Huang, S. H., and Kim, K. S. (1996) Infect. Immun. 64, 146-153[Abstract]
6. Prasadarao, N. V., Wass, C. A., Huang, S. H., and Kim, K. S. (1999) Infect. Immun. 67, 1131-1138[Abstract/Free Full Text]
7. Wang, Y., Huang, S. H., Wass, C. A., Stins, M. F., and Kim, K. S. (1999) Infect. Immun. 67, 4751-4756[Abstract/Free Full Text]
8. Prasadarao, N. V., Wass, C. A., Stins, M. F., Shimada, H., and Kim, K. S. (1999) Infect. Immun. 67, 5775-5783[Abstract/Free Full Text]
9. Reddy, M. A., Wass, C. A., Kim, K. S., Schlaepfer, D. D., and Prasadarao, N. V. (2000) Infect. Immun. 68, 6423-6430[Abstract/Free Full Text]
10. Reddy, M. A., Prasadarao, N. V., Wass, C. A., and Kim, K. S. (2000) J. Biol. Chem. 275, 36769-36774[Abstract/Free Full Text]
11. Caprioli, A., Falbo, V., Ruggeri, F. M., Baldassarri, L., Bisicchia, R., Ippolito, G., Romoli, E., and Donelli, G. (1987) J. Clin. Microbiol. 25, 146-149[Abstract/Free Full Text]
12. Falbo, V., Famiglietti, M., and Caprioli, A. (1992) Infect. Immun. 60, 2182-2187[Abstract/Free Full Text]
13. Caprioli, A., Falbo, V., Roda, L. G., Ruggen, F. M., and Zona, C. (1983) Infect. Immun. 39, 1300-1306[Abstract/Free Full Text]
14. Falzano, L., Fiorentini, C., Donelli, G., Michel, E., Kocks, C., Cossart, P., Cabanie, L., Oswald, E., and Boquet, P. (1993) Mol. Microbiol. 9, 1247-1254[Medline] [Order article via Infotrieve]
15. Fiorentini, C., Fabbri, A., Matarrese, P., and Falzano, L. (1998) Biochem. Biophys. Res. Commun. 241, 341-346
16. Flatau, G., Lemichez, E., Gauthier, M., Chardin, P., Paris, S., Fiorentini, C., and Boquet, P. (1997) Nature 387, 729-733[CrossRef][Medline] [Order article via Infotrieve]
17. Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M., and Aktories, K. (1997) Nature 387, 725-729[CrossRef][Medline] [Order article via Infotrieve]
18. Vouret-Craviari, V., Grall, D., Flatau, G., Pouyssegur, J., Boquet, P., and Van Obberghen-Schilling, E. (1999) Infect. Immun. 67, 3002-3008[Abstract/Free Full Text]
19. Taylor, R. K., Manoil, C., and Mekalanos, J. J. (1989) J. Bacteriol. 171, 1870-1878[Abstract/Free Full Text]
20. Falbo, V., Pace, T., Picci, L., Pizzi, E., and Caprioli, A. (1993) Infect. Immun. 61, 4909-4914[Abstract/Free Full Text]
21. Stins, M. F., Gilles, F., and Kim, K. S. (1997) J. Neuroimmunol. 76, 81-90[CrossRef][Medline] [Order article via Infotrieve]
22. Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., and Der, C. J. (1995) Mol. Cell. Biol. 15, 6443-6453[Abstract]
23. Tzima, E., Del Pozo, M. A., Shattil, S. J., Chien, S., and Schwartz, M. A. (2001) EMBO J. 20, 4639-4647[CrossRef][Medline] [Order article via Infotrieve]
24. Bodie, S. L., Ford, I., Greaves, M., and Nixon, G. F. (2001) Biochem. Biophys. Res. Commun. 287, 71-76[CrossRef][Medline] [Order article via Infotrieve]
25. Huang, S. H., Wass, C., Fu, Q., Prasadarao, N. V., Stins, M., and Kim, K. S. (1995) Infect. Immun. 63, 4470-4475[Abstract]
26. Jin, S., and Exton, J. H. (2000) Biochem. Biophys. Res. Commun. 277, 718-721[CrossRef][Medline] [Order article via Infotrieve]
27. Kim, K. S., Itabashi, H., Gemski, P., Sadoff, J., Warren, R. L., and Cross, A. S. (1992) J. Clin. Invest. 90, 897-905[Medline] [Order article via Infotrieve]
28. Fournout, S., Dozois, C. M., Odin, M., Desautels, C., Peres, S., Herault, F., Daigle, F., Segafredo, C., Laffitte, J., Oswald, E., Fairbrother, J. M., and Oswald, I. P. (2000) Infect. Immun. 68, 839-847[Abstract/Free Full Text]
29. Rippere-Lampe, K. E., O'Brien, A. D., Conran, R., and Lockman, H. A. (2001) Infect. Immun. 69, 3954-3964[Abstract/Free Full Text]
30. Johnson, D. E., Drachenberg, C., Lockatell, C. V., Island, M. D., Warren, J. W., and Donnenberg, M. S. (2000) FEMS Immunol. Med. Microbiol. 28, 37-41[CrossRef][Medline] [Order article via Infotrieve]
31. Lacerda, H. M., Pullinger, G. D., Lax, A. J., and Rozengurt, E. (1997) J. Biol. Chem. 272, 9587-9596[Abstract/Free Full Text]
32. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]
33. Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., Obinata, T., Ohashi, K., Mizuno, K., and Narumiya, S. (1999) Science 285, 895-898[Abstract/Free Full Text]
34. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., Tsukita, S., and Tsukita, S. (1998) J. Cell Biol. 140, 647-657[Abstract/Free Full Text]
35. Wymann, M. P., and Pirola, L. (1998) Biochim. Biophys. Acta 1436, 127-150[Medline] [Order article via Infotrieve]
36. Reif, K., Nobes, C. D., Thomas, G., Hall, A., and Cantrell, D. A. (1996) Curr. Biol. 6, 1445-1455[CrossRef][Medline] [Order article via Infotrieve]
37. Cantrell, D. A. (2001) J. Cell Sci. 114, 1439-1445[Abstract]
38. Nizet, V., Kim, K. S., Stins, M., Jonas, M., Chi, E. Y., Nguyen, D., and Rubens, C. E. (1997) Infect. Immun. 65, 5074-5081[Abstract]
39. Badger, J. L., Stins, M. F., and Kim, K. S. (1999) Infect. Immun. 67, 4208-4215[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Mittal and N. V. Prasadarao
Outer Membrane Protein A Expression in Escherichia coli K1 Is Required to Prevent the Maturation of Myeloid Dendritic Cells and the Induction of IL-10 and TGF-{beta}
J. Immunol., August 15, 2008; 181(4): 2672 - 2682.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
R. P. Fagan, M. A. Lambert, and S. G. J. Smith
The Hek Outer Membrane Protein of Escherichia coli Strain RS218 Binds to Proteoglycan and Utilizes a Single Extracellular Loop for Adherence, Invasion, and Autoaggregation
Infect. Immun., March 1, 2008; 76(3): 1135 - 1142.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
B. Mokri-Moayyed, G. J. Goldsworthy, and N. A. Khan
Development of a novel ex vivo insect model for studying virulence determinants of Escherichia coli K1
J. Med. Microbiol., January 1, 2008; 57(1): 106 - 110.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
N. A. Khan and G. J. Goldsworthy
Novel Model To Study Virulence Determinants of Escherichia coli K1
Infect. Immun., December 1, 2007; 75(12): 5735 - 5739.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
G. Parthasarathy, Y. Yao, and K. S. Kim
Flagella Promote Escherichia coli K1 Association with and Invasion of Human Brain Microvascular Endothelial Cells
Infect. Immun., June 1, 2007; 75(6): 2937 - 2945.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C.-H. Teng, Y. Xie, S. Shin, F. Di Cello, M. Paul-Satyaseela, M. Cai, and K. S. Kim
Effects of ompA Deletion on Expression of Type 1 Fimbriae in Escherichia coli K1 Strain RS218 and on the Association of E. coli with Human Brain Microvascular Endothelial Cells.
Infect. Immun., October 1, 2006; 74(10): 5609 - 5616.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
S. Alsam, S. R. Jeong, J. Sissons, R. Dudley, K. S. Kim, and N. A. Khan
Escherichia coli interactions with Acanthamoeba: a symbiosis with environmental and clinical implications
J. Med. Microbiol., June 1, 2006; 55(6): 689 - 694.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
Y. Yao, Y. Xie, and K. S. Kim
Genomic Comparison of Escherichia coli K1 Strains Isolated from the Cerebrospinal Fluid of Patients with Meningitis
Infect. Immun., April 1, 2006; 74(4): 2196 - 2206.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. Sissons, K. S. Kim, M. Stins, S. Jayasekera, S. Alsam, and N. A. Khan
Acanthamoeba castellanii Induces Host Cell Death via a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Infect. Immun., May 1, 2005; 73(5): 2704 - 2708.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
B. Korczak, J. Frey, J. Schrenzel, G. Pluschke, R. Pfister, R. Ehricht, and P. Kuhnert
Use of Diagnostic Microarrays for Determination of Virulence Gene Patterns of Escherichia coli K1, a Major Cause of Neonatal Meningitis
J. Clin. Microbiol., March 1, 2005; 43(3): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. J. Kim, J. W. Chung, and K. S. Kim
67-kDa Laminin Receptor Promotes Internalization of Cytotoxic Necrotizing Factor 1-expressing Escherichia coli K1 into Human Brain Microvascular Endothelial Cells
J. Biol. Chem., January 14, 2005; 280(2): 1360 - 1368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Munro, G. Flatau, A. Doye, L. Boyer, O. Oregioni, J.-L. Mege, L. Landraud, and E. Lemichez
Activation and Proteasomal Degradation of Rho GTPases by Cytotoxic Necrotizing Factor-1 Elicit a Controlled Inflammatory Response
J. Biol. Chem., August 20, 2004; 279(34): 35849 - 35857.
[Abstract] [Full Text] [PDF]


Home page